Provided by Tiger Trade Technology Pte. Ltd.

ANTENGENE-B

4.650
+0.44010.45%
Volume:7.18M
Turnover:32.60M
Market Cap:3.16B
PE:-10.81
High:4.700
Open:4.270
Low:4.230
Close:4.210
52wk High:8.160
52wk Low:2.100
Shares:679.00M
HK Float Shares:679.00M
Volume Ratio:2.89
T/O Rate:1.06%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.430
ROE:-32.03%
ROA:-11.42%
PB:4.34
PE(LYR):-10.81
PS:26.47

Loading ...

CICC Increases Holdings in ANTENGENE-B by 627,000 Shares at HK$3.06 Per Share

Stock News
·
Mar 09

ANTENGENE-B (06996) Releases February 2026 Monthly Return

Bulletin Express
·
Mar 05

ANTENGENE-B Shares Surge Over 11% Following $1.2 Billion Licensing Agreement with UCB

Stock News
·
Mar 05

Antengene, Sino Biopharmaceutical Shares Jump After New Drug Licensing Deals

Dow Jones
·
Mar 04

ANTENGENE-B Shares Surge Over 11% at Open on UCB Licensing Deal for CD19/CD3 Bispecific Antibody

Stock News
·
Mar 04

Antengene (6996.HK) and UCB Sign Global License Agreement for ATG-201

Bulletin Express
·
Mar 04

ANTENGENE-B Inks Exclusive Global Licensing Deal with UCB for ATG-201

Stock News
·
Mar 04

Antengene Corp - Units Entered Into a License Agreement With Ucb

THOMSON REUTERS
·
Mar 04

Antengene Corp - Units Eligible to Receive Future Success-Based Development and Commercial Milestone Payments of up to USD1.1 Bln

THOMSON REUTERS
·
Mar 04

BRIEF-Antengene And UCB Enter Global License Agreement For ATG-201, A CD19/CD3 Bispecific T-Cell Engager For Autoimmune Diseases

Reuters
·
Mar 04

Antengene and Ucb Enter Global License Agreement for Atg-201, a Cd19/Cd3 Bispecific T-Cell Engager for Autoimmune Diseases

THOMSON REUTERS
·
Mar 04

Antengene Corp - to Receive $80 Mln Upfront, Eligible for Over $1.1 Bln in Milestones and Royalties

THOMSON REUTERS
·
Mar 04

Antengene Secures South Korea Reimbursement Approval for XPOVIO in Second Multiple Myeloma Indication

Reuters
·
Mar 02

Antengene-B Shares Surge Over 6% Following Clinical Collaboration Agreement with Junshi Bio

Stock News
·
Feb 25

Antengene Clinches Clinical Collaboration With Junshi Biosciences on ATG-037 and JS207 Combo

Reuters
·
Feb 25

Antengene Announces Clinical Collaboration With Junshi Biosciences to Explore the Synergistic Potential of Atg-037 (Oral Cd73 Inhibitor) in Combination With Js207 (Pd-1/Vegf Bsab)

THOMSON REUTERS
·
Feb 25

Global Market Insights: Penny Stocks To Watch In February 2026

Simply Wall St.
·
Feb 11

Antengene (06996) Releases January 2026 Monthly Return: No Changes to Issued Shares

Bulletin Express
·
Feb 04

Antengene Showcases Pipeline Progress at J.P. Morgan Healthcare Conference

Reuters
·
Jan 16

Antengene Leads The Charge In Global With 2 Other Penny Stocks

Simply Wall St.
·
Jan 08